Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $3.6 million.

  • Ironwood Pharmaceuticals' Share-based Compensation fell 5663.34% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.0 million, marking a year-over-year decrease of 4706.07%. This contributed to the annual value of $29.8 million for FY2024, which is 673.33% down from last year.
  • Ironwood Pharmaceuticals' Share-based Compensation amounted to $3.6 million in Q3 2025, which was down 5663.34% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Share-based Compensation registered a high of $8.7 million during Q4 2023, and its lowest value of $3.6 million during Q3 2025.
  • In the last 5 years, Ironwood Pharmaceuticals' Share-based Compensation had a median value of $6.6 million in 2022 and averaged $6.6 million.
  • In the last 5 years, Ironwood Pharmaceuticals' Share-based Compensation soared by 4384.4% in 2022 and then tumbled by 5663.34% in 2025.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' Share-based Compensation stood at $6.1 million in 2021, then rose by 19.72% to $7.3 million in 2022, then grew by 19.38% to $8.7 million in 2023, then crashed by 47.54% to $4.6 million in 2024, then fell by 20.89% to $3.6 million in 2025.
  • Its Share-based Compensation stands at $3.6 million for Q3 2025, versus $4.5 million for Q2 2025 and $5.3 million for Q1 2025.